How Has the SMC Patient and Clinician Engagement (Pace) Process Been Used in Assessments of End-Of-Life Medicines and Medicines to Treat Very Rare Conditions?

Value in Health - United Kingdom
doi 10.1016/j.jval.2015.09.1350
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Assessment of Medicines for Very Rare Conditions: Review of a New Approach Within the Scottish Medicines Consortium

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Effects of Medicines Used to Treat Gastrointestinal Diseases on the Pharmacokinetics of Coadministered Drugs: A PEARRL Review

Journal of Pharmacy and Pharmacology
PharmacologyPharmaceutical Science
2018English

Procedures and Methods of Benefit Assessments for Medicines in Germany

European Journal of Health Economics
Health PolicyEconomicsEconometricsFinance
2008English

How Has Child Maltreatment Surveillance Data Been Used in Canada?

Health Research Policy and Systems
MedicineHealth Policy
2014English

Pharmacovigilance of Medicines for Rare and Ultrarare Diseases

Therapeutic Advances in Drug Safety
Pharmacology
2018English

Increasing Transparency and the Patient Voice in HTA of New Medicines

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Safe and Sound: Applying Quality Use of Medicines to High‐risk Medicines

Journal of Pharmacy Practice and Research
PharmacologyPharmacy
2018English

Access to Medicines in Resource-Limited Settings: The End of a Golden Decade?

Global Advances In Health and Medicine
Medicine
2012English

The European Medicines Agency Facilitates Access to Medicines in Low- And Middle-Income Countries

Expert Review of Clinical Pharmacology
MedicineToxicologyPharmaceuticsPharmacology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy